Initial clinical experience with Myxo-ETlogix**Myxo-ETlogix is a trade name of Edwards Lifesciences LLC, Irvine, Calif. mitral valve repair ring

Patrick M McCarthy*, E. C. McGee, Vera H Rigolin, Q. Zhao, H. Subačius, A. L. Huskin, S. Underwood, B. J. Kane, Issam A Mikati, G. Gang, Robert O Bonow

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Complexity of mitral valve repair for myxomatous disease has led to low adoption. We report initial experience with a new ring designed specifically for myxomatous disease, the Myxo-ETlogix (Edwards Lifesciences LLC, Irvine, Calif). Methods: From March 15, 2006, through November 19, 2007, 129 patients underwent mitral valve surgery for pure myxomatous disease, and 124 valves (96.1%) were repaired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring (Edwards) in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic anterior motion and a larger orifice to accommodate elongated leaflets and decrease need for sliding plasty. Direct mitral valve measurements were made. Sizing was based on A2 height, and choice of ring type was based on unresected leaflet heights. Results: There was no operative mortality or lasting perioperative morbidity. The Myxo-ETlogix group had taller A2, P1, P2, and P3 leaflet segments than the Physio group (P ≤ .003). Only 1 sliding plasty was performed for asymmetry in the Myxo-ETlogix group. Predischarge and follow-up echocardiograms (n = 338 in 124 patients) disclosed transient nonobstructive chordal systolic anterior motion in 3 echocardiograms in 3 patients. No patients had 2+ or greater mitral regurgitation. At discharge, 5.7% had 1+ mitral regurgitation; this proportion was 17.3% at last follow-up (mean 6.1 ± 4.4 months). Conclusion: In initial experience with the Myxo-ETlogix ring, nonobstructive systolic anterior motion has been rare and obstructive systolic anterior motion not observed. Ongoing prospective echocardiographic and clinical studies will elucidate the role of this etiology-specific ring.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume136
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Mitral Valve
Names
Mitral Valve Insufficiency
varespladib methyl
Prospective Studies
Morbidity
Mortality

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{87e912bdc0f54e97b89bbbbd930a58b3,
title = "Initial clinical experience with Myxo-ETlogix**Myxo-ETlogix is a trade name of Edwards Lifesciences LLC, Irvine, Calif. mitral valve repair ring",
abstract = "Objective: Complexity of mitral valve repair for myxomatous disease has led to low adoption. We report initial experience with a new ring designed specifically for myxomatous disease, the Myxo-ETlogix (Edwards Lifesciences LLC, Irvine, Calif). Methods: From March 15, 2006, through November 19, 2007, 129 patients underwent mitral valve surgery for pure myxomatous disease, and 124 valves (96.1{\%}) were repaired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring (Edwards) in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic anterior motion and a larger orifice to accommodate elongated leaflets and decrease need for sliding plasty. Direct mitral valve measurements were made. Sizing was based on A2 height, and choice of ring type was based on unresected leaflet heights. Results: There was no operative mortality or lasting perioperative morbidity. The Myxo-ETlogix group had taller A2, P1, P2, and P3 leaflet segments than the Physio group (P ≤ .003). Only 1 sliding plasty was performed for asymmetry in the Myxo-ETlogix group. Predischarge and follow-up echocardiograms (n = 338 in 124 patients) disclosed transient nonobstructive chordal systolic anterior motion in 3 echocardiograms in 3 patients. No patients had 2+ or greater mitral regurgitation. At discharge, 5.7{\%} had 1+ mitral regurgitation; this proportion was 17.3{\%} at last follow-up (mean 6.1 ± 4.4 months). Conclusion: In initial experience with the Myxo-ETlogix ring, nonobstructive systolic anterior motion has been rare and obstructive systolic anterior motion not observed. Ongoing prospective echocardiographic and clinical studies will elucidate the role of this etiology-specific ring.",
author = "McCarthy, {Patrick M} and McGee, {E. C.} and Rigolin, {Vera H} and Q. Zhao and H. Subačius and Huskin, {A. L.} and S. Underwood and Kane, {B. J.} and Mikati, {Issam A} and G. Gang and Bonow, {Robert O}",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.jtcvs.2008.02.013",
language = "English (US)",
volume = "136",
pages = "73--81",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

Initial clinical experience with Myxo-ETlogix**Myxo-ETlogix is a trade name of Edwards Lifesciences LLC, Irvine, Calif. mitral valve repair ring. / McCarthy, Patrick M; McGee, E. C.; Rigolin, Vera H; Zhao, Q.; Subačius, H.; Huskin, A. L.; Underwood, S.; Kane, B. J.; Mikati, Issam A; Gang, G.; Bonow, Robert O.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 136, No. 1, 01.07.2008, p. 73-81.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Initial clinical experience with Myxo-ETlogix**Myxo-ETlogix is a trade name of Edwards Lifesciences LLC, Irvine, Calif. mitral valve repair ring

AU - McCarthy, Patrick M

AU - McGee, E. C.

AU - Rigolin, Vera H

AU - Zhao, Q.

AU - Subačius, H.

AU - Huskin, A. L.

AU - Underwood, S.

AU - Kane, B. J.

AU - Mikati, Issam A

AU - Gang, G.

AU - Bonow, Robert O

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Objective: Complexity of mitral valve repair for myxomatous disease has led to low adoption. We report initial experience with a new ring designed specifically for myxomatous disease, the Myxo-ETlogix (Edwards Lifesciences LLC, Irvine, Calif). Methods: From March 15, 2006, through November 19, 2007, 129 patients underwent mitral valve surgery for pure myxomatous disease, and 124 valves (96.1%) were repaired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring (Edwards) in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic anterior motion and a larger orifice to accommodate elongated leaflets and decrease need for sliding plasty. Direct mitral valve measurements were made. Sizing was based on A2 height, and choice of ring type was based on unresected leaflet heights. Results: There was no operative mortality or lasting perioperative morbidity. The Myxo-ETlogix group had taller A2, P1, P2, and P3 leaflet segments than the Physio group (P ≤ .003). Only 1 sliding plasty was performed for asymmetry in the Myxo-ETlogix group. Predischarge and follow-up echocardiograms (n = 338 in 124 patients) disclosed transient nonobstructive chordal systolic anterior motion in 3 echocardiograms in 3 patients. No patients had 2+ or greater mitral regurgitation. At discharge, 5.7% had 1+ mitral regurgitation; this proportion was 17.3% at last follow-up (mean 6.1 ± 4.4 months). Conclusion: In initial experience with the Myxo-ETlogix ring, nonobstructive systolic anterior motion has been rare and obstructive systolic anterior motion not observed. Ongoing prospective echocardiographic and clinical studies will elucidate the role of this etiology-specific ring.

AB - Objective: Complexity of mitral valve repair for myxomatous disease has led to low adoption. We report initial experience with a new ring designed specifically for myxomatous disease, the Myxo-ETlogix (Edwards Lifesciences LLC, Irvine, Calif). Methods: From March 15, 2006, through November 19, 2007, 129 patients underwent mitral valve surgery for pure myxomatous disease, and 124 valves (96.1%) were repaired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring (Edwards) in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic anterior motion and a larger orifice to accommodate elongated leaflets and decrease need for sliding plasty. Direct mitral valve measurements were made. Sizing was based on A2 height, and choice of ring type was based on unresected leaflet heights. Results: There was no operative mortality or lasting perioperative morbidity. The Myxo-ETlogix group had taller A2, P1, P2, and P3 leaflet segments than the Physio group (P ≤ .003). Only 1 sliding plasty was performed for asymmetry in the Myxo-ETlogix group. Predischarge and follow-up echocardiograms (n = 338 in 124 patients) disclosed transient nonobstructive chordal systolic anterior motion in 3 echocardiograms in 3 patients. No patients had 2+ or greater mitral regurgitation. At discharge, 5.7% had 1+ mitral regurgitation; this proportion was 17.3% at last follow-up (mean 6.1 ± 4.4 months). Conclusion: In initial experience with the Myxo-ETlogix ring, nonobstructive systolic anterior motion has been rare and obstructive systolic anterior motion not observed. Ongoing prospective echocardiographic and clinical studies will elucidate the role of this etiology-specific ring.

UR - http://www.scopus.com/inward/record.url?scp=46149109830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149109830&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2008.02.013

DO - 10.1016/j.jtcvs.2008.02.013

M3 - Article

C2 - 18603056

AN - SCOPUS:46149109830

VL - 136

SP - 73

EP - 81

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -